drugset / Trial / NCT05003037
Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A phase II study to assess the efficacy and safety of Surufatinib Combined With Toripalimab and Chemotherapy in patients with advanced non-squamous non-small cell lung cancer.
Timeline
- Start
- 2022-01-06
- Primary completion
- 2025-11-03
- Completion
- 2027-11-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |
| Subject | Surufatinib | Small molecule | 250 mg | Oral |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |